Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Six UK studies investigating stereotactic ablative radiotherapy (SABR) are currently open. Many of these involve the treatment of oligometastatic disease at different locations in the body. Members of all the trial management groups collaborated to generate a consensus document on appropriate organ at risk dose constraints. Values from existing but older reviews were updated using data from current studies. It is hoped that this unified approach will facilitate standardised implementation of SABR across the UK and will allow meaningful toxicity comparisons between SABR studies and internationally.

Original publication

DOI

10.1016/j.clon.2017.09.007

Type

Journal article

Journal

Clin Oncol (R Coll Radiol)

Publication Date

01/2018

Volume

30

Pages

5 - 14

Keywords

Constraints, OAR, SABR, SBRT, normal tissue, stereotactic radiotherapy, Consensus, Guidelines as Topic, Humans, Radiosurgery, United Kingdom